Associated products


Our Abpromise guarantee covers the use of ab22106 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 3 µg/ml. Detects a band of approximately 97 kDa (predicted molecular weight: 66 kDa).


  • FunctionReceptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells.
  • Tissue specificityUbiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland.
  • Involvement in diseaseDefects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early onset deafness and loss of dentition.
    Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.
    Defects in TNFRSF11A are the cause of osteopetrosis autosomal recessive type 7 (OPTB7) [MIM:612301]; also called osteoclast-poor osteopetrosis with hypogammaglobulinemia. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia.
  • Sequence similaritiesContains 4 TNFR-Cys repeats.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD 265 antibody
    • CD265 antibody
    • FEO antibody
    • LOH18CR1 antibody
    • Loss of heterozygosity 18 chromosomal region 1 antibody
    • mRANK antibody
    • ODFR antibody
    • OFE antibody
    • OPTB7 antibody
    • Osteoclast differentiation factor receptor antibody
    • OSTS antibody
    • Paget disease of bone 2 antibody
    • PDB 2 antibody
    • PDB2 antibody
    • RANK antibody
    • Receptor activator of NF KB antibody
    • Receptor activator of NF-KB antibody
    • receptor activator of nuclear factor kappa B antibody
    • TNFRSF11A antibody
    • TNR11_HUMAN antibody
    • TRANCER antibody
    • Tumor necrosis factor receptor superfamily member 11a NFKB activator antibody
    • Tumor necrosis factor receptor superfamily member 11a activator of NFKB antibody
    • Tumor necrosis factor receptor superfamily member 11A antibody
    see all

Anti-RANK antibody images

  • Anti-RANK antibody (ab22106) + RAW cell lysate

    Predicted band size : 66 kDa
    Observed band size : 97 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 200 kDa,62 kDa,67 kDa. We are unsure as to the identity of these extra bands.

References for Anti-RANK antibody (ab22106)

ab22106 has not yet been referenced specifically in any publications.

Product Wall

Thank you for your response.

The identities of ab13918 with canine were 81%, with 89% positives and some gaps. This is generally the absolute limit for what we consider to be effective. I chose to recommend ab22106 because it was created wit...

Read More